Heterogeneity of the coumarin anticoagulant targeted vitamin K epoxide reduction system. Study of kinetic parameters in susceptible and resistant mice (Mus musculus domesticus)

Journal of Biochemical and Molecular Toxicology

Volumn 20, Issue 5, 2006, Pages 221-229

  Lasseur, Romain ^a   Grandemange, Agnès ^a   Longin Sauvageon, Christiane ^a   Berny, Philippe ^a   Benoit, Etienne ^a  

^a CEMAGREF   (France)

Author keywords

in Vitro; Kinetic Parameters; Mus musculus domesticus; Vitamin K Epoxide Reductase; VKORC1; Warfarin Resistance

Indexed keywords

4 HYDROXYCOUMARIN DERIVATIVE; COUMARIN ANTICOAGULANT; GLYCINE; LIVER ENZYME; MENADIONE EPOXIDE; PROTEIN; TRYPTOPHAN; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; EADIE HOFTSTEE; ENZYME ACTIVITY; GENE; GENE MUTATION; GENOTYPE; IN VITRO STUDY; KINETICS; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; MOUSE; MOUSE STRAIN; NONHUMAN; NONLINEAR REGRESSION ANALYSIS; NUCLEOTIDE SEQUENCE; PLOTS AND CURVES; SINGLE NUCLEOTIDE POLYMORPHISM; VKORC1 GENE;

ANIMALS; ANTICOAGULANTS; BASE SEQUENCE; CATALYTIC DOMAIN; DNA; DRUG RESISTANCE; KINETICS; MICE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MOLECULAR SEQUENCE DATA; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; WARFARIN;

MUS MUSCULUS DOMESTICUS;

EID: 33750034331     PISSN: 10956670     EISSN: 10990461     Source Type: Journal    
DOI: 10.1002/jbt.20144     Document Type: Article

References (34)

1. Linder MW, Looney S, Adams JE III, Johnson N, Antonino-Green D, Lacefield N, Bukaveckas BL, Valdes RJ. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb 2002;14:227-232.
2. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D, Deloukas P. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005;5:262-270.
3. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz H-J, Lappegard K, Seifried E, Scharrer I, Tuddenham EGD, Müller CR, Strom TM, Oldenburg J. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004;27:537-541.
4. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, Loriot MA. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005;106:135-140.
5. Sconce E, Khan T, Wynne H, Avery P, Monkhouse L, King B, Wood P, Kesteven P, Daly A, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristic upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005;106:2329-2333.
6. Boyle CM. Case of apparent resistance of Rattus norvegicus berkenhout to anticoagulant poisons. Nature 1960;188: 517-525.
7. Lund M. Resistance to the second-generation anticoagulant rodenticides. In: Clark DO, editor. Rodent biology, Proceedings of the 11th Vertebrate Pest Conference, Davis, CA, USA, 23-26 May 1983. New York: Academic Press, 1984. pp 89-94.
8. Jackson WB, Ashton AD, Delventhal K. Overview of anticoagulant rodenticide usage and resistance. In: Suttie JW, editor. Current advances in vitamin K research. New York: Elsevier Science Publishers, 1988. pp 381-388.
9. Sutcliffe FA, MacNicoll AD, Gibson GG. Hepatic microsomal warfarin metabolism in warfarin-resistant and susceptible mouse strains: influence of pre-treatment with cytochrome P-450 inducers. Chem Biol Interact 1990;75:171-184.
10. Dodsworth E. A review of biochemical mechanisms of warfarin resistance in the house mouse. Pestic Sci 1995;43:57-59.
11. Morgan DG, Petras ML. Variability in response to warfarin in natural populations of the house mouse. Genetics 1979;91:S84.
12. Siddiqi Z, Blaine WD. Anticoagulant resistance in house mouse in Toronto, Canada. Environ Health Rev 1982;26:49-51.
13. Misenheimer TM, Lund M, Miller Baker LA, Suttie JW. Biochemical basis of warfarin and bromadiolone resistance in the house mouse. Mus musculus domesticus. Biochem Pharmacol 1994;47:673-678.
14. Suttie J. Vitamin K. In: Deluca H, editor. Handbook of lipid research. New York: Plenum Press, 1978. pp 3-16.
15. Hildebrandt EF, Suttie JW. Mechanism of coumarin action: sensitivity of vitamin K metabolizing enzymes of normal and warfarin-resistant rat liver. Biochemistry 1982;21:2406-2411.
16. Cain D, Hutson S, Wallin R. Warfarin resistance is associated with a protein component of the vitamin K 2,3-epoxide reductase enzyme complex in rat liver. Thromb Haemostasis 1998;80:128-133.
17. Wallin R, Hutson SM, Cain D, Sweatt A, Sane DC. A molecular mechanism for genetic warfarin resistance in the rat. FASEB J 2001;15:2542-2544.
18. Pelz J, Rost S, Hünerberg M, Fregin A, Heiberg A-C, Baert K, MacNicoll A, Prescott C, Walker A-S, J. Oldenburg J, Müller C. The genetic basis of resistance to anticoagulants in rodents. Genetics 2005;170:1839-1847.
19. Lasseur R, Longin-Sauvageon C, Videmann B, Billeret M, Berny P, Benoit E. Warfarin resistance in a French strain of rats. J Biochem Mol Toxicol 2005;19:379-385.
20. MacNicoll AD. A review of biochemical mechanisms of warfarin resistance in the house mouse. Pestic Sci 1995;43:57-59.
21. Wallace ME, MacSwinney FJ. A major gene controlling warfarin-resistance in the house mouse. J Hyg 1976;76:173-181.
22. EPPO. Guideline for the evaluation of resistance to plant protection products: testing rodents for resistance to anticoagulant rodenticides. EPPO Bull 1995;25:575-593.
23. Moroni C, Longin-Sauvageon C, Benoit E. The flavin-containing monooxygenase in rat liver: evidence for the expression of a second form different from FMO1. Biochem Biophys Res Commun 1995;212:820-826.
24. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
25. Thijssen H. Vitamin K epoxide reductase of Scottish resistance genes is not irreversibly blocked by warfarin. Biochem Pharmacol 1987;36:2753-2757.
26. Thijssen H, Baars L. Microsomal warfarin binding and vitamin K 2,3-epoxide reductase. Biochem Pharmacol 1989;38:1115-1120.
27. Misenheimer TM, Suttie JW. Warfarin resistance in a Chicago strain of rats. Biochem Pharmacol 1990;40:2079-2084.
28. Tishler M, Fieser LF, Wendler NL. Hydro, oxido and other derivatives of vitamin K1 related compounds. J Am Chem Soc 1940;62:2866-2871.
29. Goodstadt L, Ponting C. Vitamin K epoxide reductase: homology, active site and catalytic mechanism. Trends Biochem Sci 2004;29:289-292.
30. Thijssen H, Janssen C, Mosterd J. Warfarin resistance: biochemical evaluation of a warfarin-resistant wild brown rat. Biochem Pharmacol 1989;38:3129-3132.
31. MacNicoll AD, Nadian AK, Townsend MG. Inhibition by warfarin of liver microsomal vitamin K-reductase in warfarin-resistant and susceptible rats. Biochem Pharmacol 1983;33:1331-1336.
32. Tie J, Nicchitta C, von Heijne G, Stafford D. Membrane topology mapping of vitamin K epoxide reductase by in vitro translation/cotranslocation. J Biol Chem 2005;280:16410-16416.
33. Rost S, Fregin A, Hünerberg M, Bevans C, Müller C, Oldenburg J. Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1. Evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin. Thromb Haemost 2005;94:780-786.
34. Begent LA, Hill AP, Steventon GB, Hutt AJ, Pallister CJ, Cowell DC. Characterization and purification of the vitamin K1 2,3 epoxide reductases system from rat liver. J Pharm Pharmacol 2001;54:481-486.